Abstract 8P
Background
Tumor metabolism and tumor-specific immune responses are one of integral compartments consisting of tumor niche. Several lines of evidence showed that tumor cells and tumor-infiltrating lymphocytes (TILs) compete for glucose in tumor microenvironment and that tumor metabolic parameter correlates with localized immune markers in several solid tumors. With this background, we compared standardized uptake value (SUV) of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET-CT) and stromal TILs in breast cancer (1≥cm).
Methods
Two hundred two patients were identified among those who underwent preoperative 18F-FDG-PET-CT and had tumor size equal to or larger than 1cm. Maximum SUV was obtained from 18F-FDG-PET-CT. Stromal TILs was evaluated according to standardized methodology proposed by the international TIL Working Group. We identified factors related with high TILs (≥40%) using multiple logistic-regression. All tumors were treatment-naïve.
Results
There was a significant but weak correlation between continuous SUV and continuous TILs (p = 0.002, R = 0.215). Mean TILs was significantly high in Ki-67 labeling index ≥14%, nuclear/histologic grade 3, and HER2-positive or triple-negative breast cancer (TNBC). In multivariable analysis, aggressive subtypes as HER2-positive or TNBC and continuous SUV were significantly associated with high TILs ≥40%.
Conclusions
We found that SUV was associated with TILs in breast cancer and provide clinical evidence that elevated glucose uptake of breast tumors may be affected by TILs in tumor micromileu.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract